Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.46 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.44 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | PRKCG | P05129 | 1/20 | 0.40 |
| ▸ | PRKCB | P05771 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | PRKCH | P24723 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25167912 | 0.86 | SLC2A1 (0.41) | PYGBFBP1PRKD3PRKCGPRKCB | |
| SCHEMBL11178984 | 0.82 | PYGB (0.45) | PYGBLGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL30514366 | 0.82 | PYGB (0.53) | PYGBLGALS3GAAPRKD3PRKCG | |
| SCHEMBL17728077 | 0.79 | ALDH1A1 (0.47) | PYGBLGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL28677194 | 0.79 | LGALS3 (0.40) | PYGBLGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL27988153 | 0.79 | LGALS9 (0.53) | LGALS1LGALS3LGALS9 | |
| SCHEMBL13063075 | 0.79 | LGALS1 (0.50) | PYGBLGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL19941494 | 0.78 | FBP1 (0.37) | PYGBFBP1PRKD3PRKCGPRKCB | |
| SCHEMBL1755358 | 0.78 | LGALS3 (0.64) | PYGBLGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL7929801 | 0.78 | LGALS3 (0.64) | PYGBLGALS1LGALS3LGALS9LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712435-B2 | Mebendazole prodrugs with enhanced solubility and oral bioavailability | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20210205271-A1 | MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. | 2021-07-08 | — | — | US | disclosed |
| EP-3749652-A1 | MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY | The Johns Hopkins University (US) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019157338-A1 | MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712435-B2 | Mebendazole prodrugs with enhanced solubility and oral bioavailability | CYP3A43, CYP3A4, CYP4B1 | PYGB 784/4885LGALS1 4647/4885LGALS3 4087/4885 |
| US-20210205271-A1 | MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY | CYP3A43, CYP3A4, CYP4B1 | PYGB 784/4885LGALS1 4647/4885LGALS3 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.